Common TitleHPTN 077
Official Title Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744[Cabotegravir]) in HIV-Uninfected Adults
Phase Phase IIA
ClinicalTrials.gov NCT02178800
Treatments
Cabotegravir
Cabotegravir
Tradename:ApretudeOther Names:Injectable cabotegravir, Long-acting injectable cabotegravirClass:Integrase Inhibitors (INSTI)Categories PREP
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
- Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
- Landovitz RJ, Zangeneh SZ, Chau G, et al. Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077. Clin Infect Dis. 2020;70:319-22.